Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of durvalumab, doxorubicin, and ifosfamide in pulmonary sarcomatoid carcinoma
KCT0004531Phase 2
Key facts
- Status
- Completed
- Start
- May 2020
- Countries
- 1
- Sponsor
- AstraZeneca
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Conditions
- lung sarcomatoid carcinoma (PSC)
01
Overview
Phase 2, single-arm trial of durvalumab, doxorubicin and ifosfamide in lung sarcomatoid carcinoma (PSC), sponsored by AstraZeneca. Started May 2020; status: completed.
02
Design
1 arm- Study design
- Non-randomizedSingle group
Durvalumab + doxorubicin + ifosfamide
Single treatment arm receiving durvalumab in combination with doxorubicin and ifosfamide for pulmonary sarcomatoid carcinoma.
03
Who it enrols
Adult patients with histologically confirmed pulmonary sarcomatoid carcinoma; healthy volunteers are not eligible.
Beyond the preview
Go deeper on KCT0004531.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004531.